100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
TEST BANK For Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 8th Edition by Nader Rifai, Verified Chapters 1 - 49, Complete Newest Version $21.99   Add to cart

Exam (elaborations)

TEST BANK For Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 8th Edition by Nader Rifai, Verified Chapters 1 - 49, Complete Newest Version

 0 view  0 purchase
  • Course
  • Tietz Fundamentals of Clinical Chemistry, 8th Edit
  • Institution
  • Tietz Fundamentals Of Clinical Chemistry, 8th Edit

TEST BANK For Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 8th Edition by Nader Rifai, Verified Chapters 1 - 49, Complete Newest Version TEST BANK For Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 8th Edition by Nader Rifai, Verified Chapters 1 - 49, Com...

[Show more]

Preview 4 out of 347  pages

  • November 13, 2024
  • 347
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • 9780323549738
book image

Book Title:

Author(s):

  • Edition:
  • ISBN:
  • Edition:
  • Tietz Fundamentals of Clinical Chemistry, 8th Edit
  • Tietz Fundamentals of Clinical Chemistry, 8th Edit
avatar-seller
nipseyscott
Test bank for Tietz Fundamentals of Clinical Chemistr
and Molecular Diagnostic
8th Edition by Nader Rifai, PhD
Chapters 1 - 4

,Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics 8th Edition Test Bank
DY DY DY DY DY DY DY DY
DY
DY DY




Table of contents:
DY DY




I. Principles Of Laboratory Medicine
DY DY DY DY




Chapter 1. Clinical Chemistry, Molecular Diagnostics, and Laboratory Medicine
DY DY DY DY DY DY DY DY




Chapter 2. Selection and Analytical Evaluation of Methods — With Statistical Techniques
DY DY DY DY DY DY DY DY DY DY DY




Chapter 3. Clinical Evaluation of Methods
DY DY DY DY DY




Chapter 4. Evidence-Based Laboratory Medicine
DY DY DY DY




Chapter 5. Establishment and Use of Reference Values
DY DY DY DY DY DY DY




Chapter 6. Specimen Collection, Processing, and Other Preanalytical Variables
DY DY DY DY DY DY DY DY




Chapter 7. Quality Management
DY DY DY




II. Analytical Techniques And Instrumentation
DY DY DY DY




Chapter 8. Principles of Basic Techniques and Laboratory Safety
DY DY DY DY DY DY DY DY




Chapter 9. Optical Techniques
DY DY DY




Chapter 10. Electrochemistry and Chemical Sensors
DY DY DY DY DY




Chapter 11. Electrophoresis
DY DY




Chapter 12. Chromatography
DY DY




Chapter 13. Mass Spectrometry
DY DY DY




Chapter 14. Enzyme and Rate Analyses
DY DY DY DY DY




Chapter 15. Immunochemical Techniques
DY DY DY




Chapter 16 Automation DY DY




Chapter 17. Point-of-Care Instrumentation
DY DY DY




III. Analytes
D Y




Chapter 18. Amino Acids, Peptides, and Proteins
DY DY DY DY DY DY




Chapter 19. Serum Enzymes
DY DY DY




Chapter 20. Tumor Markers and Cancer Genes
DY DY DY DY DY DY




Chapter 21. Kidney Function Tests — Creatinine, GFR, Urea, and Uric Acid
DY DY DY DY DY DY DY DY DY DY DY




Chapter 22. Carbohydrates
DY DY




Chapter 23. Lipids, Lipoproteins, Apolipoproteins, and Other Cardiac Risk Factors
DY DY DY DY DY DY DY DY DY




Chapter 24. Electrolytes and Blood Gases
DY DY DY DY DY




Chapter 25. Hormones DY DY




Chapter 26. Catecholamines and Serotonin
DY D Y DY DY




Chapter 27. Vitamins, Trace Elements, Nutritional Assessment
DY D Y DY DY DY DY




Chapter 28. Hemoglobin, Iron, and Bilirubin
DY DY DY DY DY




Chapter 29. Porphyrins and Porphyrias
DY DY DY DY




Chapter 30. Therapeutic Drugs and Their Management
DY DY DY DY DY DY




Chapter 31. Clinical Toxicology
DY DY DY




Chapter 32. Toxic Metals
DY D Y DY




IV. Pathophysiology
D Y




Chapter 33. Diabetes DY DY

,Chapter 34. Cardiovascular Disease
DY D Y DY




Chapter 35. Kidney Disease
DY DY DY




Chapter 36. Physiology and Disorders of Water, Electrolyte, and Acid-Base Metabolism
DY D Y DY DY DY DY DY DY DY DY




Chapter 37. Liver Disease
DY DYDY DY




Chapter 38. Gastrointestinal and Pancreatic Diseases
DY D Y DY DY DY




Chapter 39. Disorders of Bone and Mineral Metabolism
DY DYDY DY DY DY DY DY




Chapter 40. Disorders of the Pituitary Gland
DY DYDY DY DY DY DY




Chapter 41. Disorders of the Adrenal Cortex
DY D Y DY DY DY DY




Chapter 42. Thyroid Disorders
DY D Y DY




Chapter 43. Reproduction-Related Disorders
DY D Y DY




Chapter 44. Pregnancy and Prenatal Testing
DY DYDY DY DY DY




Chapter 45. Newborn Screening and Inborn Errors of Metabolism
DY D Y DY DY DY DY DY DY




Chapter 46. Pharmacogenetics
DY DY




V. Molecular Diagnostics
D Y DY




Chapter 47. Principles of Molecular Biology
DY DY DY DY DY




Chapter 48. Nucleic Acid Techniques and Applications
DY DY DY DY DY DY




Chapter 49. Genomes and Nucleic Acid Alterations
DY DY DY DY DY DY

, Chapter 01: Clinical Chemistry, Molecular Diagnostics, and Laboratory Medicine T
DY DY DY DY DY DY DY DY DY



estBank
D
Y




MULTIPLE CHOICE DY




1. An individual working in a clinical chemistry laboratory is married to a sales representati
DY DY DY DY DY DY DY DY DY DY DY DY DY



ve who works for a company that sells chemistry laboratory supplies. When the laborator
DY DY DY DY DY DY DY DY DY DY DY DY DY



y manager requests a list of needed supplies, cost of supplies, and vendors, this individua
DY DY DY DY DY DY DY DY DY DY DY DY DY DY



l onlyrecommends the spouse’s company as the vendor. This is considered to be a(n):
DY D
Y DY DY DY DY DY DY DY DY DY DY DY DY



a. accounting issue. DY



b. possible conflict of interest. DY DY DY



c. maintenance of confidentiality issue. DY DY DY



d. problem with resource allocation. DY DY DY




ANS: B DY



Concern has been raised over the interrelationships between practitioners in the medical fi
DY DY DY DY DY DY DY DY DY DY DY DY



eldand commercial suppliers of drugs, devices, equipment, etc., to the medical profession.
D
Y DY DY DY DY DY DY DY DY DY DY DY



Similarly, relationships have been scrutinized between clinical laboratorians and manufactu
DY DY DY DY DY DY DY DY DY



rers and providers of diagnostic equipment and supplies. These concerns led the National I
DY DY DY DY DY DY DY DY DY DY DY DY DY



nstitutes of Health (NIH) in 1995 to require official institutional review of financial disclo
DY DY DY DY DY DY DY DY DY DY DY DY DY



sure by researchers and management of situations in which disclosure indicates potentialco
DY DY DY DY DY DY DY DY DY DY DY D
Y



nflicts of interest. DY DY




DIF: 1 REF: DYDYDY Page 4-5 DY OBJ: 6 | 7 DY DY DY




2. A patient visits her physician stating that her prescribed painkiller is not working to red
DY DY DY DY DY DY DY DY DY DY DY DY DY DY



uce the pain following her recent surgery. A friend of the patient claims that the same p
DY DY DY DY DY DY DY DY DY DY DY DY DY DY DY DY



ainkiller“worked wonders” to reduce her pain after the same surgery. The physician stat
D
Y DY DY DY DY DY DY DY DY DY DY DY DY



es that the difference in the effect of the drug might be caused by
DY DY DY DY DY DY DY DY DY DY DY DY DY



, which is studied in pharmacogenetics.
DY DY DY DY DY



a. epidemiology
b. an inherited disease DY DY



c. a conflict of interest
DY DY DY



d. a genetic variation in drug-metabolizing enzymes
DY DY DY DY DY




ANS: D DY



Pharmacogenetics is the study of the genetic variation of drug metabolism betw DY DY DY DY DY DY DY DY DY DY DY



eenindividuals.
D
Y




DIF: 1 REF: DYDYD Y Page 3 DY OBJ: 1 DY




3. John works in a molecular diagnostics laboratory and receives a blood sample that has
DY DY DY DY DY DY DY DY DY DY DY DY DY DY



the name of a close friend printed on the bar-
DY DY DY DY DY DY DY DY DY



coded label. The genetic test that is ordered on thefriend’s sample would provide diagn
DY DY DY DY DY DY DY DY DY D
Y DY DY DY DY



ostic information about a disorder that has a poor prognosis, and the test is usually perf
DY DY DY DY DY DY DY DY DY DY DY DY DY DY DY



ormed by John. He asks a fellow employee to analyzethe sample for him and not divul
DY DY DY DY DY DY DY DY DY D
Y DY DY DY DY DY DY



ge the results. This ethical issue concerns:
DY DY DY DY DY DY



a. confidentiality of patient genetic and medical information. DY DY DY DY DY DY



b. a conflict of interest.
DY DY DY



c. resource allocation. DY



d. diagnostic accuracy. DY

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller nipseyscott. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $21.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

80796 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$21.99
  • (0)
  Add to cart